Immunopathogenesis of multiple sclerosis
- PMID: 20182567
- PMCID: PMC2824947
- DOI: 10.4103/0972-2327.58274
Immunopathogenesis of multiple sclerosis
Abstract
Multiple sclerosis (MS) is a suspected autoimmune disease in which myelin-specific CD4+ and CD8+ T cells enter the central nervous system (CNS) and initiate an inflammatory response directed against myelin and other components of the CNS. Acute MS exacerbations are believed be the result of active inflammation, and progression of disability is generally believed to reflect accumulation of damage to the CNS, particularly axonal damage. Over the last several years, the pathophysiology of MS is being appreciated to be much more complex, and it appears that the development of the MS plaque involves a large number of cell populations, including CD8+ T lymphocytes, B cells, and Th17 cells (a population of helper T cells that secrete the inflammatory cytokine IL-17). The axonal transection and degeneration that is thought to represent the basis for progressive MS is now recognized to begin early in the disease process and to continue in the progressive forms of the disease. Molecules important for limiting aberrant neural connections in the CNS have been identified, which suppress axonal sprouting and regeneration of transected axons within the CNS. Pathways have also been identified that prevent remyelination of the MS lesion by oligodendrocyte precursors. Novel neuroimaging methodologies and potential biomarkers are being developed to monitor various aspects of the disease process in MS. As we identify the pathways responsible for the clinical phenomena of MS, we will be able to develop new therapeutic strategies for this disabling illness of young adults.
Keywords: Magnetic resonance imaging; multiple sclerosis; pathogenesis; review.
Conflict of interest statement
Figures

Similar articles
-
Neuronal injury in chronic CNS inflammation.Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Best Pract Res Clin Anaesthesiol. 2010. PMID: 21619866 Review.
-
Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.Neurodegener Dis Manag. 2015 Dec;5(6):527-48. doi: 10.2217/nmt.15.50. Epub 2015 Dec 1. Neurodegener Dis Manag. 2015. PMID: 26619755 Review.
-
Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.Curr Neurol Neurosci Rep. 2021 Apr 9;21(6):26. doi: 10.1007/s11910-021-01110-5. Curr Neurol Neurosci Rep. 2021. PMID: 33835275 Review.
-
Cross-recognition of a myelin peptide by CD8+ T cells in the CNS is not sufficient to promote neuronal damage.J Neurosci. 2015 Mar 25;35(12):4837-50. doi: 10.1523/JNEUROSCI.3380-14.2015. J Neurosci. 2015. PMID: 25810515 Free PMC article.
-
Immunopathogenesis of the multiple sclerosis lesion.Curr Neurol Neurosci Rep. 2001 May;1(3):257-62. doi: 10.1007/s11910-001-0028-4. Curr Neurol Neurosci Rep. 2001. PMID: 11898527 Review.
Cited by
-
Perspectives on urological care in multiple sclerosis patients.Intractable Rare Dis Res. 2021 May;10(2):62-74. doi: 10.5582/irdr.2021.01029. Intractable Rare Dis Res. 2021. PMID: 33996350 Free PMC article. Review.
-
Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?AJNR Am J Neuroradiol. 2017 Jan;38(1):12-17. doi: 10.3174/ajnr.A4953. Epub 2016 Oct 6. AJNR Am J Neuroradiol. 2017. PMID: 27758773 Free PMC article.
-
Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis.PLoS One. 2014 Jul 21;9(7):e103151. doi: 10.1371/journal.pone.0103151. eCollection 2014. PLoS One. 2014. PMID: 25047369 Free PMC article.
-
Mucosal Administration of E-selectin Limits Disability in Models of Multiple Sclerosis.Front Mol Neurosci. 2019 Aug 27;12:190. doi: 10.3389/fnmol.2019.00190. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31507371 Free PMC article.
-
Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential treatment target.Immunol Res. 2024 Aug;72(4):554-565. doi: 10.1007/s12026-024-09471-y. Epub 2024 Mar 6. Immunol Res. 2024. PMID: 38446328 Review.
References
-
- Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354:942–55. - PubMed
-
- Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, et al. Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions. Arch Neurol. 2005;62:1345–56. - PubMed
-
- Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:246–8. - PubMed
-
- De Keyser J, Zeinstra E, Frohman E. Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch Neurol. 2003;60:132–6. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials